

Effectiveness *Curcuma Longa* to Prevent Cells Damage in Early Pregnant Mice with Acute Toxoplasmosis.

Tigor Peniel Simanjuntak,¹ Mochammad Hatta,² Syahrul Rauf,³ Andi Mardiah Tahir,³ Irawan Yusuf,⁴ Nurpuji Astuti Taslim,⁵ Robert Hotman Sirait,⁶ Silvia Arin Prabandari⁷

¹Department of Obstetrics and Gynecology, Faculty of Medicine, Christian University of Indonesia, Jakarta

²Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar

³Department of Obstetrics and Gynecology, Faculty of Medicine, Hasanuddin University, Makassar

⁴Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar, ⁵Department of nutrition, Faculty of Medicine, Hasanuddin University, Makassar

⁶Department of Anesthesiology, Faculty of Medicine, Christian University of Indonesia, Jakarta,

⁷Primate Research Center, Bogor Agricultural Institute, Bogor

Korespondensi: Tigor Peniel Simanjuntak, email: tigorpsimanjuntak@gmail.com

Abstract

Objective: To prove the effectiveness of *Curcuma longa* to prevent damage cells by analyzing FOXP3 gene expression, TNF- α level, and histopathology of placental tissue.

Methods: This study was conducted in 20 early pregnant mice, divided in 5 groups (K1-K5). K1-K4 were injected with tachyzoites. K1 and K2 were intervened with *Curcuma longa* 125 and 500 mg/kg/day. K3 were intervened with spiramycin 60 mg/kg/day, K4 were intervened with 0,2 distilled water, and K5 was not injected and intervened. IgG-IgM levels, FOXP3 mRNA expression, TNF- α level was examined serially, and placental mice were taken for histopathology examination 7 days after intervention.

Results: FOXP3 mRNA expression in K1 and K2 increased significantly 7 days after intervention compared to K4 ($p < 0.05$), however the increased of expression in two groups has no significant difference. TNF- α level in K1 and K2 decreased significantly 7 days after intervention compared to K4 ($p < 0.05$), however the decrease of level in two groups has no significant difference. Hemorrhagic and necrotic cells were not found in K1 and K2, but were found in K3 (75%) and K4 (100%).

Conclusion: *Curcuma longa* 125 mg is effective to prevent cells damage in early pregnant mice with acute toxoplasmosis.

Key words: *Curcuma longa*, Cells damage, Early pregnancy, FOXP3 gene, TNF- α , Toxoplasmosis

Efektivitas Ekstrak *Curcuma Longa* Mencegah Kerusakan Sel Pada Mencit Hamil Muda dengan Toksoplasmosis Akut.

Abstrak

Tujuan: Membuktikan efektivitas *Curcuma longa* mencegah kerusakan sel dengan menganalisis ekspresi gen FOXP3, kadar TNF- α , dan histopatologi jaringan plasenta.

Metode: Penelitian dilakukan pada 20 tikus hamil muda, dibagi dalam 5 kelompok (K1-K5). K1-K4 diinjeksi 10 takizoid toksoplasma intra abdominal. Tiga hari pasca injeksi takizoid, K1 dan K2 diintervensi dengan *Curcuma longa* 125 dan 500 mg / kg / hari. K3 diintervensi dengan spiramisin 60 mg / kg / hari, K4 diintervensi dengan 0,2 ml air suling dan K5 tidak diinjeksi dan tidak diintervensi. Kadar IgG-IgM, ekspresi mRNA FOXP3, kadar TNF- α diperiksa secara serial dan plasenta tikus diambil untuk pemeriksaan histopatologi 7 hari pasca intervensi.

Hasil: Ekspresi mRNA FOXP3 pada K1 dan K2 meningkat bermakna ($p < 0.05$) 7 hari pasca intervensi dibandingkan dengan K4 ($p < 0,05$), tetapi peningkatan ekspresi pada kedua kelompok tidak terdapat perbedaan bermakna. Kadar TNF- α pada K1 dan K2 menurun bermakna 7 hari pasca intervensi dibandingkan dengan K4 ($p < 0,05$), tetapi penurunan kadar pada dua kelompok tidak terdapat perbedaan bermakna. Hemoragik dan nekrotik sel tidak ditemukan pada K1 dan K2, tetapi ditemukan pada K3 (75%) dan K4 (100%).

Kesimpulan: *Curcuma longa* 125 mg efektif untuk mencegah kerusakan sel pada tikus hamil muda dengan toksoplasmosis akut.

Keywords: *Curcuma longa*, kerusakan sel, hamil muda, gene FOXP3, TNF- α , toxoplasmosis

Introduction

Toxoplasmosis is an infection caused by the parasite *Toxoplasma gondii*¹⁻³. *Toxoplasma* infection will stimulate the cellular and humoral immune response of the body⁴⁻⁶. The Fork head box P3 (FOXP3) gene as a regulator of the balance of cellular immunity through T-helper cell⁷. The role of FOXP3 gene is to suppress T-helper cells especially Th1 (TNF- α)⁸. When the infection occurs, FOXP3 gene expression decreases and the TNF- α levels increase^{9,10}. An excessive increase of TNF- α levels can cause thrombosis, ischemia, and necrotic cells. If this condition occurs in early pregnancy, it can cause damaged cells and abortion¹¹⁻¹³.

Curcuma longa is a plant that belongs to the rhizome group that is easy to grow and found in Asia. *Curcuma longa* from ancient times has been used as a traditional medicine and herbal therapy. Curcumin is a major component of *Curcuma longa* has been widely studied for its potent anti-inflammatory¹⁴, anti-oxidant¹⁵, anti-parasite¹⁶, and anti-microorganism^{17, 18}. This study aims to prove the effectiveness of *Curcuma longa* extract to prevent the cell damage of placental tissue in early pregnant mice with acute toxoplasmosis by analyzing the expression of *foxp3* mRNA, TNF- α levels and histopathology examination of placental mice after intervention.

Material and Methods

This research is experimental pre and post-test control groups design using 20 Balb/c female mice that were conditioned into 1-3 day(s) pregnancy that fulfill inclusion criteria (mice age 9-11 weeks, weigh 17- 20 grams, willing to eat and drink). The early pregnant mice were divided into five groups (K1 – K5), 4 mice each group. K1 – K4 were injected with 10 tachyzoites of *T. gondii* RH strain intra-peritoneal, and K5 without infection. The *Curcuma longa* extract get

use was obtained by maceration, and the curcuminoid compound was evaluated using KLT densitometry and spectrophotometry. Curcuminoid level in *C. longa* extract obtained were at 25.5%. Three days after injection of tachyzoites, K1 and K2 were each given *C. longa* extract dose of 125 and 500 mg/kg/day, K3 was given spiramycin dose of 60 mg/kg/day (positive control), K4 was given 0.2 ml distilled water (negative control), and K5 was not intervention. Each intervention was administered for 7 days.

Blood samples were taken serially (one day before tachyzoites injection, 3 days after tachyzoites injection, and 3 days and 7 days after intervention). Examination of anti-toxoplasma IgG-IgM antibody levels and TNF- α level were examined using enzyme-linked immune-sorbent assay (ELISA), (Qualitative mouse toxoplasma antibody IgG (T-IgG) ELISA Kit Cat. No: MBS9310461 and Qualitative mouse toxoplasma antibody IgM (T-IgM) ELISA Kit Cat. No: MBS9310461) and The level of TNF- α was determined with ELISA Kit (LS-Bio: Life-Span Bio-Sciences, Inc. FOXP3 gene expression by Quantitative Real-time polymerase chain reaction (q-PCR). Quantitative Real-time polymerase chain reaction (q-PCR) examination was performed using a PCR system (Applied Bio-system-Rad BT004129 USA machine) used SYBR power Green PCR Mix. FOXP3 primer is : FW-TTT ACT CGC ATG TTG CCT ACTT and RV- TCA AAT TCA TCT ACG GTC CAC ACT (NM_001199347.1), and standard of normality is GAPDH FW-CAT GGC CTT CCG TGT TCCT AND RV-GCG GAC GTC AGA TCCA (M32599.1). The examination of FOXP3 expression according to the standard procedure of q-PCR. The expression of the FOXP3 gene is inferred in the form of numbers seen on the computer monitor screen. Seven days after the intervention, the mice were sacrificed to remove the uterus containing the placenta. Examination of placental histopathology in

all samples was done to study and assessed the degree of damage of placental tissue in the form of the congestive capillary, extracellular edema, hemorrhagic and necrotic cells.

The data were processed using SPSS software and the data were statistically analyzed using paired t-test to determine the TNF- α level and FOXP3 gene expression before and after intervention. One-way Anova

test was conducted to determine the difference of TNF- α level, and FOXP3 gene expression among these 5 groups. Histopathology finding were reported in percentage, and chi-square test was performed to identify cells damage between groups. A values of $p < 0.05$ was considered significant.

Results

Table 1 Anti-Toxoplasma IgM Antibody Level before and after Intervention.

Group (K)	Anti-Toxoplasma IgM Antibody level				Cut Off Point (OD)
	A1	A2	A3	A4	
K1	0,250 ± 0,001	0,847 ± 0,012	0,534 ± 0,013	0,346 ± 0,024	
K2	0,260 ± 0,017	0,828 ± 0,010	0,517 ± 0,005	0,321 ± 0,009	
K3	0,242 ± 0,011	0,795 ± 0,012	0,564 ± 0,013	0,355 ± 0,014	0,327
K4	0,251 ± 0,011	0,826 ± 0,017	1,434 ± 0,021	1,629 ± 0,015	
K5	0,249 ± 0,007	0,302 ± 0,012	0,266 ± 0,013	0,307 ± 0,018	

Legend. K1: Group injected with tachyzoites and intervered with *C. Longa* dose of 125 mg/kgbb. K2: Group injected with tachyzoites and intervered with *C. Longa* dose of 500 mg/kgbb. K3: Group injected with tachyzoites and intervered with Spiramycin dose of 60 mg/kgbb. K4: Group injected with tachyzoites and intervered with distilled water 0,2 ml. K5: Group was not injected with tachyzoites and was not intervered. A1:one day before tachyzoites injection, A2: Three days after tachyzoites injection, A3 and A4 Three and seven days after intervention.

Table 2 Anti-Toxoplasma IgG Antibody Level before and after Intervention.

Group (K)	Anti-Toxoplasma IgG Antibody level				Cut Off point (OD)
	A1	A2	A3	A4	
K1	0,162 ± 0,008	0,348 ± 0,015	0,449 ± 0,023	0,441 ± 0,013	
K2	0,153 ± 0,006	0,362 ± 0,021	0,462 ± 0,012	0,455 ± 0,008	
K3	0,154 ± 0,010	0,340 ± 0,008	0,439 ± 0,004	0,461 ± 0,021	0,302
K4	0,155 ± 0,009	0,354 ± 0,010	0,753 ± 0,007	1,365 ± 0,009	
K5	0,132 ± 0,012	0,154 ± 0,010	0,152 ± 0,015	0,139 ± 0,015	

Legend. K1: Group injected with tachyzoites and intervered with *C. Longa* dose of 125 mg/kgbb. K2: Group injected with tachyzoites and intervered with *C. Longa* dose of 500 mg/kgbb. K3: Group injected with tachyzoites and intervered with Spiramycin dose of 60 mg/kgbb. K4: Group injected with tachyzoites and intervered with distilled water 0,2 ml. K5: Group was not injected with tachyzoites and was not intervered. A1:one day before tachyzoites injection, A2: Three days after tachyzoites injection, A3 and A4 Three and seven days after intervention.

Table 3 FOXP3 Gene Expression before and after Intervention.

Group (K)	FOXP3 Gene Expression							
	A1		A2		A3		A4	
K1	9,98 ±	0,14	7,98 ±	0,21	12,03 ±	0,13	9,88 ±	0,23
K2	9,96 ±	0,14	8,07 ±	0,17	12,12 ±	0,32	9,87 ±	0,13
K3	10,02 ±	0,15	8,54 ±	0,09	11,93 ±	0,12	10,14 ±	0,15
K4	10,18 ±	0,12	8,85 ±	0,15	7,09 ±	0,15	6,12 ±	0,14
K5	10,00 ±	0,19	10,20 ±	0,14	10,06 ±	0,19	9,90 ±	0,16

Legend. K1: Group injected with tachyzoites and intervered with *C. Longa* dose of 125 mg/kgbb. K2: Group injected with tachyzoites and intervered with *C. Longa* dose of 500 mg/kgbb. K3: Group injected with tachyzoites and intervered with Spiramycin dose of 60 mg/kgbb. K4: Group injected with tachyzoites and intervered with distilled water 0,2 ml. K5: Group was not injected with tachyzoites and was not intervered. A1:one day before tachyzoites injection, A2: Three days after tachyzoites injection, A3 and A4 Three and seven days after intervention.

Table 4 TNF-α Level before and after Intervention.

Group (K)	TNF-α Level (pg/ml)			
	A1	A2	A3	A4
K1	36,738 ± 0,015	301,708 ± 0,025	130,23 ± 0,013	81,976 ± 0,010
K2	31,310 ± 0,013	285,244 ± 0,018	144,102 ± 0,013	88,611 ± 0,015
K3	38,219 ± 0,013	305,425 ± 0,017	137,139 ± 0,013	85,870 ± 0,013
K4	35,814 ± 0,013	292,432 ± 0,020	352,750 ± 0,019	558,436 ± 0,020
K5	36,517 ± 0,008	36,517 ± 0,007	34,410 ± 0,010	36,517 ± 0,005

Legend. K1: Group injected with tachyzoites and intervered with *C. Longa* dose of 125 mg/kgbb. K2: Group injected with tachyzoites and intervered with *C. Longa* dose of 500 mg/kgbb. K3: Group injected with tachyzoites and intervered with Spiramycin dose of 60 mg/kgbb. K4: Group injected with tachyzoites and intervered with distilled water 0,2 ml. K5: Group was not injected with tachyzoites and was not intervered. A1:one day before tachyzoites injection, A2: Three days after tachyzoites injection, A3 and A4 Three and seven days after intervention.

Table5. Histological Finding after Intervention

Group (K)	Histological Finding			
	Congestive Capiler (%)	Extracellular Edema (%)	Haemorrhagic (%)	Necrotic cell (%)
K1	100	50	0	0
K2	100	75	0	0
K3	100	100	75	75
K4	100	100	100	100
K5	100	0	0	0

Legend. K1: Group injected with tachyzoites and intervered with *C. Longa* dose of 125 mg/kgbb. K2: Group injected with tachyzoites and intervered with *C. Longa* dose of 500 mg/kgbb. K3: Group injected with tachyzoites and intervered with Spiramycin dose of 60 mg/kgbb. K4: Group injected with tachyzoites and intervered with distilled water 0,2 ml. K5: Group was not injected with tachyzoites and was not intervered. A1:one day before tachyzoites injection, A2: Three days after tachyzoites injection, A3 and A4 Three and seven days after intervention.

Discussion

This study was conducted in mice that were conditioned 1-3 days of pregnancy and acute toxoplasmosis. The anti-toxoplasma IgG-IgM antibody levels increased significantly 3 days after injection of *T. gondii* tachyzoites (Table 1 and 2), it means that the mice have been acute toxoplasmosis before intervention. Our previous study also found that anti-toxoplasma IgM and IgG antibody levels increased significantly 24 hours and 48 hours after injection of 10 *T. gondii* tachyzoites⁵

The expression of FOXP3 gene in this study decreased significantly ($p < 0.05$) 3 days after injection of 10 *T. gondii* tachyzoites. The other researchers also reported decreased the FOXP3 gene expression during acute infection⁹⁻¹⁰. Three and Seven days after intervention with *C. longa* extract dose of 125 and 500 mg/kg/days, the FOXP3 gene expression increased significantly ($p < 0.05$), however the increased of FOXP3 gene expression in two groups has no significant difference. The curcumin can increase the expression of the FOXP3 gene through the transforming growth factor- β (TGF- β) pathway. The curcumin induces conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF- β

induction of transcription factor FOXP3¹⁹ Several researchers also reported that FOXP3 gene expression increased 7-day after intervention with curcumin²⁰⁻²¹.

In this study the TNF- α levels increased significantly ($p < 0.01$) 3 days after tachyzoites injection and decreased significantly ($p < 0.05$) 3 and 7 days after *C. longa* extract intervention dose of 125 and 500 mg / kg / day, however the decrease of TNF- α level in two groups has no significant difference. Guo *et al*, also reported that TNF- α levels increased 7 days after curcumin intervention dose of 100 mg²².

In this study, the histopathology examination of placental tissue 7 days after intervention with curcuma longa extract was not found hemorrhage and necrotic cells, but in the positive control group found hemorrhagic and necrotic cells were 75% of sample and 100% in negative control group.

Based on the findings this study it can be concluded that *Curcuma longa* extract dose of 125 mg / kg /day for 7 days effectively to prevent the damage of placental tissue cells in early pregnant mice with acute toxoplasmosis. *Curcuma longa* can prevent cell damage by increasing foxp3 gene expression and decreasing TNF- α levels. The use of curcuma longa extract at dose of 125

mg / kg / day for 7 days may be considered as supportive therapy in early pregnancy with acute toxoplasmosis, however further research is needed.

Conclusion

Curcuma longa extract dose of 125 mg/kg/day for 7 days orally effective to prevent cells damage placental tissue in early pregnant mice with acute toxoplasmosis.

References

1. Black MW, Boothroyd JC. Lytic Cycle of *Toxoplasma Gondii*. *Microbiol Mol Biol Rev.*2000; 64(3) : 607–623.
2. Khan A, Dubey JP, Su C, Ajioka JW, Rosenthal BM, Sibley LD. Genetic analyses of atypical *Toxoplasma gondii* strains reveal a fourth clonal lineage in North America. *Int J Parasitol.*2011; 41(6):645–655
3. Wang L, Chen H, Liu D, Huo X, Gao J, Song X, *et al.* Genotypes and Mouse Virulence of *Toxoplasma gondii* **Isolates from Animals and Humans in China**. *PLoS One.* 2013; 8(1): e53483
4. Kang H, Jack S, Remington, Suzuki Y. Decreased resistance of B cell-deficient mice to infection with *T. gondii* despite unimpaired expression of IFN- γ , TNF- α , and inducible nitric oxide synthase. *J Immunol.* 2000; 164: 2629–2634.
5. Simanjuntak TP, Hatta M, Sirait RH, Karo M, Sirait LI, Aritonang TR, *et al.* Analysis concentration of *Toxoplasma gondii* on anti-toxoplasma IgG-IgM antibody Levels, and the outcomes of pregnancy in mice Balb/c. *Open J Obstetric and Gynecology.*2017; 7: 281–9.
6. Prigione I, Chiesa S, Taverna P, *et al.* T cell mediated immune responses to *Toxoplasma gondii* in pregnant women with primary toxoplasmosis. *Microbes Infect.* 2006;8 : 552–560.
7. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor FOXP3. *Immunity.* 2005; 22: 329–41.
8. Cosmi L, Liotta F, Angeli R. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. *Blood.* 2004; 103: 3117–3121.
9. Ge YY, Zhang L, Zhang G, Wu JP, Tan MJ, Hu W, *et al.* In Pregnant Mice, the Infection of *Toxoplasma gondii* Causes the Decrease of CD4+CD25+ Regulatory T Cells. *Parasite Immunology.* 2008; 30: 471–481.
10. Chen JL, Ge YY, Zhang J, Qiu XY, Qiu JF. The dysfunction of CD4+CD25+ regulatory T Cells contributes to the abortion of mice caused by *Toxoplasma gondii* excreted- secreted antigen in early pregnancy. *PLOS ONE.* 2013; 8(7): e69012
11. Clark DA, Ding JW, Chaouat G, Coulam CB, August C, Levy GA. The Emerging Role of Immunoregulation of Fibrinogen-Related Procoagulant Fgl2 in the Success or Spontaneous Abortion of Early Pregnancy in Mice and Humans. *Am J Repro Immunol.* 1999; 42(1): 37–43.
12. Clark DA, Ding JW, Yu G, Levy GA, Gorczynski RM. Fgl 2 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2. *Mol Hum Reprod.*2001; 7:185–194.
13. Haider S, Knofler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. *Placenta.* 2009; 30(2):111–123.
14. Anggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. *British j of*

- Pharmacology.2013; 169:1672–92.
15. Motterlini R, Oresti R, Bassi R, JGreen C. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. *Free Radical Biology and Medicine*. 2000; 8(15): 1303–12.
 16. Najia A, Al- Zanbagi. In vivo effect of some spices extracts on the *Toxoplasma gondii* tachyzoites. *J Family community Med*. 2009; 16(2): 59–65.
 17. Moghadamtousi SZ, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, antifungal activity of kurkumin. *Biomed Research internasional*.2014: 1–12.
 18. Tyagi P, Singh M, Kumari H, Kumari A, Mukhopadhyay. Bacterial activity of curcumin is associated with damaging of bacterial membrane. *PLOS ONE*. 2015; 10(3): e012313
 19. Chen W, Jin W, Hardegen N, Lei KJ, Li Li, Marinos N. Conversion of Periferal CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF- β Induction of Transcription Factor FOXP3. *J experimental Medicine*. 2003; 198(12): 1875–1886.
 20. Cong Y, Wang L, Konrad A, Ashoeb T, Elson CO. Curcumin Induces the Tolerogenic Dendritic Cell that Promotes Differentiation of Intestine – Protective Regulatory T Cells. *Eur.J. Immunol*. 2009; 39:3134–3146.
 21. Zhao HM, Xu R, Huang XY, Cheng SM, Huang MF, Yue HY, *et al*. Curcumin Inproves Regulatory T Cells in Gut-Associated Lymhoid Tissue of Colitis Mice. *J Gastroenterol*. 2016; 22(23): 5374–5383.
 22. Guo Y-Z World, Ping He, Ai-Min Feng. Effect of curcumin on expressions of NF-Kb, and IL-8 in placental tissue of premature birth of infected mice. *Asian Pacific Journal of Tropical Medicine*. 2017; 10(2): 175–8.